The size of the Lung Cancer Surgery Market in the Asia Pacific has been estimated at USD 7.20 billion in 2024 and is projected to reach USD 11.09 billion by 2029, growing at a CAGR of 9% from 2024 to 2029.
Lung Cancer is a kind of cancer that starts in Lung tissue or its surrounding parts. There are various types of treatments available to treat cancer like Chemotherapy, Radiotherapy, Laser Therapy, and Surgery. Surgery involves the removal of an infected parts from the lungs. In some cases, surgery will be used with other treatment methods to cure cancer. Surgery is only used if cancer cells don’t spread very near to the heart.
Rising pollution levels, an increasing number of cigarette smokers, rising incidence and prevalence of Lung Cancer and rising geriatric population are some of the major factors driving the market.
However, the high cost of Lung Cancer surgery is restraining the growth of the market.
On the basis of procedure, Minimally Invasive surgeries are expected to grow at the highest CAGR owing to the rising awareness among people of the importance of early detection of lung cancer and the advantages of Minimally Invasive Surgeries over conventional surgeries.
On the basis of the device, the Surgical Instruments segment is expected to dominate the market owing to the shorter lifespan of devices and wider adoption of these devices.
Geographically, Europe has the second-largest market after North America owing to its Advanced Healthcare facilities and higher awareness among people and greater economic stability.
Notable companies dominating the Asia Pacific Lung Cancer Surgery Market include Ethicon US LLC, Intuitive Surgical Inc., AngioDynamics Inc., Olympus Corporation, Accuray Inc., Ackermann Instrumente GmbH, Teleflex Inc., KARL STORZ GmbH, Scanlan International Inc., and Trokamed GmbH.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region